反应详情

Following the procedure in Example 1, Step 6, 4-[3-(4-fluoro-phenoxy)-benzylidene]-piperidine hydrochloride (200 mg, 0.625 mmol, from Example 18, Step 3) and phenyl 3,4-dimethylisoxazol-5-ylcarbamate (160 mg, 0.40 mmol) were used to provide the title compound (196 mg). MS (APCI 10 V) AP+ 422.2, 284.2, AP− 420.2; 1H NMR (400 MHz, CD3OD) δ ppm 1.83 (s, 3H) 2.18 (s, 3H) 2.42 (td, J=5.76, 1.10 Hz, 2H) 2.51 (td, J=5.88, 1.13 Hz, 2H) 3.47-3.52 (m, 2H) 3.57-3.63 (m, 2H) 6.40 (s, 1H) 6.77-6.84 (m, 2H) 6.94-6.98 (m, J=7.78, 1.45, 0.77, 0.77 Hz, 1H) 6.98-7.03 (m, 2H) 7.05-7.13 (m, 2H) 7.29 (t, J=7.85 Hz, 1H).